Insulet Corporation (NASDAQ:PODD) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Insulet Corporation (NASDAQ:PODD) have received an average recommendation of “Moderate Buy” from the twenty-six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $193.48.

Several research firms have recently weighed in on PODD. Truist Financial reiterated a “hold” rating and set a $153.00 price objective (down from $210.00) on shares of Insulet in a report on Wednesday, August 5th. Raymond James Financial reaffirmed an “outperform” rating and issued a $180.00 price target on shares of Insulet in a research note on Thursday, August 6th. Barclays assumed coverage on shares of Insulet in a report on Tuesday. They set a “positive” rating and a $150.00 price objective on the stock. Wall Street Zen cut Insulet from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 9th. Finally, Royal Bank Of Canada dropped their price target on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th.

Insulet Price Performance

Insulet stock opened at $134.73 on Wednesday. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $9.34 billion, a P/E ratio of 25.18, a PEG ratio of 1.07 and a beta of 1.11. The business has a 50-day moving average of $143.68 and a 200-day moving average of $161.13. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the prior year, the firm earned $1.17 earnings per share. The business’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities analysts anticipate that Insulet will post 6.51 EPS for the current year.

Institutional Trading of Insulet

A number of institutional investors have recently made changes to their positions in the business. Moody National Bank Trust Division boosted its stake in shares of Insulet by 150.9% during the 3rd quarter. Moody National Bank Trust Division now owns 5,442 shares of the medical instruments supplier’s stock worth $710,000 after buying an additional 3,273 shares during the last quarter. QRG Capital Management Inc. boosted its position in Insulet by 142.4% during the second quarter. QRG Capital Management Inc. now owns 3,851 shares of the medical instruments supplier’s stock valued at $586,000 after purchasing an additional 2,262 shares during the last quarter. Talon Private Wealth LLC boosted its position in Insulet by 92.0% during the second quarter. Talon Private Wealth LLC now owns 5,124 shares of the medical instruments supplier’s stock valued at $780,000 after purchasing an additional 2,455 shares during the last quarter. Sequoia Financial Advisors LLC grew its stake in Insulet by 26.0% in the second quarter. Sequoia Financial Advisors LLC now owns 4,042 shares of the medical instruments supplier’s stock valued at $615,000 after purchasing an additional 834 shares in the last quarter. Finally, Tidal Investments LLC grew its stake in Insulet by 24.1% in the second quarter. Tidal Investments LLC now owns 16,773 shares of the medical instruments supplier’s stock valued at $2,554,000 after purchasing an additional 3,253 shares in the last quarter.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.